Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CREBBP | Q92793 | 20/20 | 0.86 |
| ▸ | BRD4 | O60885 | 2/20 | 0.57 |
| ▸ | EP300 | Q09472 | 2/20 | 0.57 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.55 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.55 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.55 |
| ▸ | BRD7 | Q9NPI1 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19657721 | 1.00 | CREBBP (0.86) | CREBBPBRD4EP300TRIM24BRD3 | |
| SCHEMBL19657658 | 0.92 | CREBBP (1.00) | CREBBPBRD4EP300TRIM24BRD3 | |
| SCHEMBL29704457 | 0.92 | CREBBP (1.00) | CREBBPBRD4EP300TRIM24BRD3 | |
| SCHEMBL19657682 | 0.86 | CREBBP (1.00) | CREBBPBRD4EP300TRIM24BRD3 | |
| SCHEMBL19657734 | 0.84 | CREBBP (0.78) | CREBBPBRD4EP300TRIM24BRD3 | |
| SCHEMBL19657612 | 0.83 | CREBBP (0.74) | CREBBPBRD4EP300 | |
| SCHEMBL29704498 | 0.83 | CREBBP (0.74) | CREBBPBRD4EP300 | |
| SCHEMBL19657688 | 0.76 | CREBBP (0.76) | CREBBPBRD4EP300TRIM24BRD3 | |
| SCHEMBL19657737 | 0.76 | CREBBP (1.00) | CREBBPBRD4EP300 | |
| SCHEMBL19657414 | 0.76 | CREBBP (1.00) | CREBBPBRD4EP300TRIM24BRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115028617-A | Heterocyclic inhibitors of CBP/EP300 and their use in the treatment of cancer | 基因泰克公司 | 2022-09-09 | — | — | CN | disclosed |
| CN-109476641-B | Heterocyclic inhibitors of CBP/EP300 and their use in the treatment of cancer | 基因泰克公司 | 2022-07-05 | — | — | CN | disclosed |